Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 153-159

  Cianfrocca, Mary ^a   Cooley, Timothy P ^a   Lee, Jeannette Y ^a   Rudek, Michelle A ^a   Scadden, David T ^a   Ratner, Lee ^a   Pluda, James M ^a   Figg, William D ^a   Krown, Susan E ^a   Dezube, Bruce J ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; EDEMA; GENE OVEREXPRESSION; HEADACHE; HUMAN; KAPOSI SARCOMA; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HIV INFECTIONS; HUMANS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; SARCOMA, KAPOSI; STATISTICS, NONPARAMETRIC; TETRACYCLINE; TETRACYCLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036137547     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.153     Document Type: Article

References (33)

1. Incidence of human immunodeficiency virus related and non-related malignancies in a large cohort of homosexual men
2. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
3. Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells
4. The matrix degrading metalloproteinases
5. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
6. Gelatinase A activity directly modulates melanoma cell adhesion and spreading
7. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A
8. Expression of multiple matrix metalloproteinases and urokinase-type plasminogen activator in cultured Kaposi's sarcoma cells
9. Inhibition by human recombinant tissue inhibitor of matrix metalloproteinases of human amnion invasion and lung colonization by murine B16-F 10 melanoma cells
10. Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant human tissue inhibitor of metallopoteinases
11. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
12. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice
13. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases
14. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
15. Inhibition of the metastatic spread of B16-BL 6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
16. Matrix metalloproteinase inhibitor BB-94 (batimistat) inhibits human colon tumor growth and spread in a patient like orthotopic model in nude mice
17. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs
18. High-performance liquid chromatography with mass spectometry detection for quantitating col-3, a chemically modified tetracycline, in human plasma
19. Noncompartmental analysis based on statistical moment theory
20. A phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
21. Body-surface area as a basis for dosing of anticancer agents: Science, myth or habit?
22. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma
23. The role of HIV-1 in the pathogenesis of AIDS-related Kaposi's sarcoma: The importance of an inflammatory and angiogenic milieu
24. Pharmacokinetics and bioavailability of doxycycline in humans
25. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects
26. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia
27. Demethylchlortetracycline: A new tetracycline antibiotic that yields greater and more sensitive antibacterial activity
28. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid
29. Clinical pharmacologic studies with minocycline
30. Influence of repetitive dosing of tetracyclines on biologic half-life in serum
31. Comparative serum binding, distribution and excretion of tetracycline and a new analogue, methacycline
32. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms